Eva Jack's move comes after the transition of the US-based team's other managing directors, Maggie LeFlore and Frank Top, to become venture partners.
Eva Jack (pictured), managing director at AstraZeneca’s corporate venturing unit MedImmune Ventures, has left to become chief business officer at Novartis-backed Pulmatrix.
Jack’s move comes after the transition of the US-based team’s other managing directors, Maggie LeFlore and Frank Top, to become venture partners.
In April, Ron Laufer, a co-founder of Lilly Ventures, was hired as senior managing director. Laufer has recruited Samuel Wu, ex-principal at SV Life Sciences for eight years, and Isai Peimer as a principal.
